TY - GEN
T1 - Polymorphism of Apolipoprotein e (APOE) gene in head and neck cancer
AU - Eugene, Lius Putri Felicia
AU - Gultom, Ferry Pergamus
AU - Midoen, Yurnadi Hanafi
AU - Suhartono, Antonius Winoto
AU - Marchelina, Triana
AU - Auerkari, Elza Ibrahim
N1 - Funding Information:
Financial support from the Indonesian Ministry of Research, Technology and Higher Education Universitas Indonesian is greatly appreciated (EIA, PDUPT number 985/UNZ.R3.1/PPM00.01/2018).
Publisher Copyright:
© 2019 Author(s).
PY - 2019/4/9
Y1 - 2019/4/9
N2 - One of the risk factors for head and neck cancer (HNC) is genetics. Apolipoprotein E (APOE) polymorphism is known for affecting antioxidant activity which counteracts free radicals triggering cancer pathogenesis. The primary goal is to assess any relationship between APOE polymorphism and HNC. The study is a descriptive research using analytic laboratory. Samples were obtained from Oral Biology Laboratory Faculty of Dentistry, University of Indonesia. The DNA used for evaluation consisted of 50 samples from patients with head and neck cancer and 50 controls. Polymorphism was identified using PCR-RFLP technique. As the result of the research, there are 100% polymorphisms in HNC and control groups. Fisher test results for genotype shows p=0,356 where the cancer group were 50 individuals with heterozygotes, 76% of individuals with the genotype ϵ2 / ϵ3, while 24% of individuals with the ϵ3 / ϵ4 genotype. There was no individual with homozygous genotypes wild type ϵ3 / ϵ3. In the control group, 49 individuals gained heterozygotes and 1 individual had homozygous genotypes. 80% of the control individuals had the genotype ϵ2 / ϵ3, 18% had the ϵ3 / ϵ4 genotype, and 2% with the ϵ4 / ϵ4 gene. Genotype distribution does not match Hardy-Weinberg equilibrium because the p value was less than 0.05. In conclusion, there was a relationship between APOE polymorphism and HNC as a reverse causality but there was no significant difference between APOE polymorphism and HNC.
AB - One of the risk factors for head and neck cancer (HNC) is genetics. Apolipoprotein E (APOE) polymorphism is known for affecting antioxidant activity which counteracts free radicals triggering cancer pathogenesis. The primary goal is to assess any relationship between APOE polymorphism and HNC. The study is a descriptive research using analytic laboratory. Samples were obtained from Oral Biology Laboratory Faculty of Dentistry, University of Indonesia. The DNA used for evaluation consisted of 50 samples from patients with head and neck cancer and 50 controls. Polymorphism was identified using PCR-RFLP technique. As the result of the research, there are 100% polymorphisms in HNC and control groups. Fisher test results for genotype shows p=0,356 where the cancer group were 50 individuals with heterozygotes, 76% of individuals with the genotype ϵ2 / ϵ3, while 24% of individuals with the ϵ3 / ϵ4 genotype. There was no individual with homozygous genotypes wild type ϵ3 / ϵ3. In the control group, 49 individuals gained heterozygotes and 1 individual had homozygous genotypes. 80% of the control individuals had the genotype ϵ2 / ϵ3, 18% had the ϵ3 / ϵ4 genotype, and 2% with the ϵ4 / ϵ4 gene. Genotype distribution does not match Hardy-Weinberg equilibrium because the p value was less than 0.05. In conclusion, there was a relationship between APOE polymorphism and HNC as a reverse causality but there was no significant difference between APOE polymorphism and HNC.
KW - Apolipoprotein E
KW - genetic polymorphism
KW - head and neck cancer
UR - http://www.scopus.com/inward/record.url?scp=85064831752&partnerID=8YFLogxK
U2 - 10.1063/1.5096758
DO - 10.1063/1.5096758
M3 - Conference contribution
AN - SCOPUS:85064831752
T3 - AIP Conference Proceedings
BT - 3rd Biomedical Engineering''s Recent Progress in Biomaterials, Drugs Development, and Medical Devices
A2 - Wulan, Praswasti P.D.K.
A2 - Gozan, Misri
A2 - Astutiningsih, Sotya
A2 - Ramahdita, Ghiska
A2 - Dhelika, Radon
A2 - Kreshanti, Prasetyanugraheni
PB - American Institute of Physics Inc.
T2 - 3rd International Symposium of Biomedical Engineering''s Recent Progress in Biomaterials, Drugs Development, and Medical Devices, ISBE 2018
Y2 - 6 August 2018 through 8 August 2018
ER -
